Quizartinib approved to treat adult patients with a type of blood cancer

Twitter

Linkedin

Facebook

email

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloi…

Follow this news feed: